Skip to content

Clinical RCT on the improvement of cardiopulmonary function in patients with novel coronavirus infection during the recovery period by comprehensive sequential therapy of Chinese medicine

Clinical RCT on the improvement of cardiopulmonary function in patients with novel coronavirus infection during the recovery period by comprehensive sequential therapy of Chinese medicine

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081131
Enrollment
Unknown
Registered
2024-02-23
Start date
2023-06-11
Completion date
Unknown
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

long-covid syndrome

Interventions

treatment group:Chinese Herbal Medicine and Snap-Needle Therapy
control group:Western medicine for symptomatic treatment

Sponsors

The Third Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ?Patients who meet the above diagnostic criteria of traditional Chinese medicine and western medicine; ? Age 18-65 years old, gender is not limited; ? Patients more than 1 week after negative nucleic acid or antigen test; ? Patients with symptoms of impaired cardiopulmonary function, such as cough, fatigue, palpitation, etc., which last for no more than half a year after turning negative from nucleic acid or antigen test; ? Patient's TCM evidence points, according to the symptoms in the recovery period, the primary symptoms are evaluated according to 0, 1, 2, 3 points, and the secondary symptoms are evaluated according to the presence or absence of the symptoms, using 1 or 0 points, and the sum of the scores is recorded as the TCM evidence points, and the higher the score, the more serious the condition is. ? Patients volunteered to be tested and signed an informed consent form.

Exclusion criteria

Exclusion criteria: ?Patients with severe interstitial lung disease, bronchiectasis, and other underlying lung diseases; ? Patients with underlying diseases such as congenital respiratory malformations and congenital heart disease; ? Patients with severe cardiac, hepatic, renal dysfunction and abnormal coagulation function; ?Patients with diseases that affect cognitive function, such as alcoholism, drug addiction or psychotropic substance abuse; ? People with history of needle fainting and skin infection at the site of needling; ? Patients who are allergic to Chinese medicinal preparations; ? Pregnant or lactating women; ? Those who are participating in other clinical trials or those who have participated in other clinical trials for less than 3 months. Those who meet any of the above criteria should be excluded.

Design outcomes

Primary

MeasureTime frame
Chinese Medicine Score;

Secondary

MeasureTime frame
Medical outcomes study short-from 36(SF-36);Cardiopulmonary exercise testing,CPET;Pittsburgh sleep quality index,PSQI;Chest CT;

Countries

China

Contacts

Public ContactLin Xianming

The Third Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine

linxianming66@126.com+86 189 5807 7816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026